Azacitidine as salvage therapy for acute myeloid leukemia in a severely ill patient

  • Harry Ross Powers Department of Medicine, Medical College of Georgia, Georgia Regents University, Augusta, GA, United States.
  • Moshe Bachar Department of Medicine, Medical College of Georgia, Georgia Regents University, Augusta, GA, United States.
  • Natasha Savage Department of Pathology, Medical College of Georgia, Georgia Regents University, Augusta, GA; Charlie Norwood Veteran Affairs Medical Center, Augusta, GA, United States.
  • Michael Toscano Department of Pathology, Medical College of Georgia, Georgia Regents University, Augusta, GA, United States.
  • Paul M. Dainer | pdainer@gru.edu Charlie Norwood Veteran Affairs Medical Center, Augusta, GA; Section of Hematology/Oncology, Medical College of Georgia, Georgia Regents University, Augusta, GA, United States.

Abstract

Acute myeloid leukemia (AML) is a hematological malignancy of myeloid progenitor cells that disrupt normal hematopoiesis. Current chemotherapy regimens result in complete remission in many cases; however, there exists no standard efficacious therapy for refractory acute myeloid leukemia. The hypomethylating agent, azacitidine, is effective in a limited number of such cases. We present a 57-year-old Filipino male with acute myeloid leukemia who was refractory to two induction chemotherapy regimens; however, he achieved complete remission after palliative therapy with azacitidine. We report this case to demonstrate the efficacy of azacitidine in refractory acute myeloid leukemia. Although the effectiveness of azacitidine in improving overall survival has been shown, this case demonstrates the effect on remission induction in high risk AML. Further studies are needed to delineate subsets of acute myeloid leukemia in which azacitidine will serve as effective therapy and to identify other targeted agents that may potentiate its effects.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.
Published
2014-09-30
Info
Issue
Section
Case Reports
Keywords:
leukemia, acute myeloblastic/monocytic/refractory, azacitidine, salvage chemotherapy
Statistics
  • Abstract views: 1732

  • PDF: 458
  • HTML: 361
How to Cite
Powers, H. R., Bachar, M., Savage, N., Toscano, M., & Dainer, P. M. (2014). Azacitidine as salvage therapy for acute myeloid leukemia in a severely ill patient. Hematology Reports, 6(3). https://doi.org/10.4081/hr.2014.5516